vs

Side-by-side financial comparison of Finward Bancorp (FNWD) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $16.5M, roughly 1.2× Finward Bancorp). Finward Bancorp runs the higher net margin — 12.0% vs -66.3%, a 78.3% gap on every dollar of revenue. On growth, Finward Bancorp posted the faster year-over-year revenue change (1.1% vs -8.7%). Over the past eight quarters, Pulmonx Corp's revenue compounded faster (-0.5% CAGR vs -19.1%).

Finward Bancorp is a U.S.-headquartered regional bank holding company. It offers a full range of retail and commercial banking products and services, including deposit accounts, personal and mortgage loans, small business financing, and wealth management solutions, primarily serving individual customers and small to mid-sized enterprises in its local operating regions.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

FNWD vs LUNG — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.2× larger
LUNG
$20.6M
$16.5M
FNWD
Growing faster (revenue YoY)
FNWD
FNWD
+9.7% gap
FNWD
1.1%
-8.7%
LUNG
Higher net margin
FNWD
FNWD
78.3% more per $
FNWD
12.0%
-66.3%
LUNG
Faster 2-yr revenue CAGR
LUNG
LUNG
Annualised
LUNG
-0.5%
-19.1%
FNWD

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FNWD
FNWD
LUNG
LUNG
Revenue
$16.5M
$20.6M
Net Profit
$2.0M
$-13.7M
Gross Margin
77.9%
Operating Margin
11.0%
-40.9%
Net Margin
12.0%
-66.3%
Revenue YoY
1.1%
-8.7%
Net Profit YoY
-5.6%
5.5%
EPS (diluted)
$0.46
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FNWD
FNWD
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$16.5M
$22.6M
Q3 25
$17.4M
$21.5M
Q2 25
$16.6M
$23.9M
Q1 25
$15.5M
$22.5M
Q4 24
$16.3M
$23.8M
Q3 24
$14.9M
$20.4M
Q2 24
$14.6M
$20.8M
Net Profit
FNWD
FNWD
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$2.0M
$-10.4M
Q3 25
$3.5M
$-14.0M
Q2 25
$2.2M
$-15.2M
Q1 25
$455.0K
$-14.4M
Q4 24
$2.1M
$-13.2M
Q3 24
$606.0K
$-14.1M
Q2 24
$143.0K
$-15.3M
Gross Margin
FNWD
FNWD
LUNG
LUNG
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
FNWD
FNWD
LUNG
LUNG
Q1 26
-40.9%
Q4 25
11.0%
-43.8%
Q3 25
20.5%
-66.9%
Q2 25
12.7%
-62.0%
Q1 25
4.0%
-64.6%
Q4 24
16.3%
-56.5%
Q3 24
2.7%
-69.3%
Q2 24
0.9%
-75.2%
Net Margin
FNWD
FNWD
LUNG
LUNG
Q1 26
-66.3%
Q4 25
12.0%
-46.1%
Q3 25
20.1%
-64.9%
Q2 25
12.9%
-63.6%
Q1 25
2.9%
-64.1%
Q4 24
12.9%
-55.4%
Q3 24
4.1%
-69.4%
Q2 24
1.0%
-73.7%
EPS (diluted)
FNWD
FNWD
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$0.46
$-0.25
Q3 25
$0.81
$-0.34
Q2 25
$0.50
$-0.38
Q1 25
$0.11
$-0.36
Q4 24
$0.50
$-0.33
Q3 24
$0.14
$-0.36
Q2 24
$0.03
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FNWD
FNWD
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$174.7M
$45.8M
Total Assets
$2.0B
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FNWD
FNWD
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$69.8M
Q3 25
$76.5M
Q2 25
$75.5M
Q1 25
$74.6M
Q4 24
$70.9M
Q3 24
$63.3M
Q2 24
$63.5M
Total Debt
FNWD
FNWD
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
FNWD
FNWD
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$174.7M
$54.1M
Q3 25
$165.5M
$60.0M
Q2 25
$154.3M
$69.1M
Q1 25
$151.8M
$77.7M
Q4 24
$151.4M
$85.8M
Q3 24
$159.6M
$93.9M
Q2 24
$148.6M
$101.2M
Total Assets
FNWD
FNWD
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$2.0B
$129.3M
Q3 25
$2.1B
$138.3M
Q2 25
$2.1B
$147.2M
Q1 25
$2.0B
$150.7M
Q4 24
$2.1B
$162.8M
Q3 24
$2.1B
$167.4M
Q2 24
$2.1B
$172.6M
Debt / Equity
FNWD
FNWD
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FNWD
FNWD
LUNG
LUNG
Operating Cash FlowLast quarter
$9.9M
Free Cash FlowOCF − Capex
$9.0M
FCF MarginFCF / Revenue
54.8%
Capex IntensityCapex / Revenue
5.2%
Cash ConversionOCF / Net Profit
4.99×
TTM Free Cash FlowTrailing 4 quarters
$10.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FNWD
FNWD
LUNG
LUNG
Q1 26
Q4 25
$9.9M
$-7.1M
Q3 25
$1.2M
$-8.2M
Q2 25
$4.8M
$-3.9M
Q1 25
$-3.8M
$-13.2M
Q4 24
$9.8M
$-6.7M
Q3 24
$-3.7M
$-7.2M
Q2 24
$2.8M
$-5.8M
Free Cash Flow
FNWD
FNWD
LUNG
LUNG
Q1 26
Q4 25
$9.0M
$-7.1M
Q3 25
$1.0M
$-8.3M
Q2 25
$4.5M
$-4.0M
Q1 25
$-4.0M
$-13.5M
Q4 24
$6.7M
$-6.8M
Q3 24
$-4.2M
$-7.7M
Q2 24
$1.1M
$-6.2M
FCF Margin
FNWD
FNWD
LUNG
LUNG
Q1 26
Q4 25
54.8%
-31.4%
Q3 25
6.0%
-38.4%
Q2 25
27.0%
-16.6%
Q1 25
-25.7%
-60.0%
Q4 24
41.2%
-28.8%
Q3 24
-28.5%
-37.6%
Q2 24
7.6%
-30.0%
Capex Intensity
FNWD
FNWD
LUNG
LUNG
Q1 26
Q4 25
5.2%
0.1%
Q3 25
0.9%
0.4%
Q2 25
1.7%
0.2%
Q1 25
1.2%
1.3%
Q4 24
18.8%
0.5%
Q3 24
3.4%
2.0%
Q2 24
11.2%
2.3%
Cash Conversion
FNWD
FNWD
LUNG
LUNG
Q1 26
Q4 25
4.99×
Q3 25
0.34×
Q2 25
2.22×
Q1 25
-8.37×
Q4 24
4.66×
Q3 24
-6.15×
Q2 24
19.23×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons